MMA Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

MMA Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-370	Closed	-$266K	–	123
2023 Q2	$266K	Sell	370 -18	-5%	-$13.9K	0.16%	101
2023 Q1	$319K	Hold	388	–	–	0.23%	73
2022 Q4	$280K	Sell	388 -1	-0.3%	-$738	0.23%	72
2022 Q3	$268K	Buy	389 +20	+5%	+$12.6K	0.23%	71
2022 Q2	$218K	Hold	369	–	–	0.19%	83
2022 Q1	$227K	Buy	+369	New	+$233K	0.18%	92

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MMA Asset Management's REGN Position: Q3 2023 in Review

MMA Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 370 shares — an estimated $266K sold.

MMA Asset Management first reported a position in REGN in Q1 2022 and held it in 6 quarters. The position peaked at $319K in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

MMA Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
MMA Asset Management sold 370 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $266K.
MMA Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 6 quarters.
MMA Asset Management's Regeneron Pharmaceuticals position peaked at $319K in Q1 2023.
1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on MMA Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.